Latest news
- Business30 September 2024
Adalvo on Track to Finalize Global Fidaxomicin Dossier by End of 2024
Adalvo reports significant progress in the development of Fidaxomicin Film Coated Tablets, with the dossier on track for global submission by the end of 2024. As we gear up for the...
- Achievements13 September 2024
Adalvo Nominated for Six Global Generics & Biosimilars and CPHI 2024 Awards
At Adalvo we are driven by our commitment to our partner network, dedicated to making a meaningful impact and improving patient lives globally. We are proud to share that Adalvo has been...
- Business12 September 2024
Adalvo Submits DCP Filing for Teduglutide on Day-1
Adalvo has submitted its DCP filing for Teduglutide on Day-1 following the expiry of Data Exclusivity. Teduglutide has been developed for the treatment of short bowel syndrome (SBS), a rare condition...
- Business12 August 2024
Adalvo signs an exclusive LSA with Dr. Reddy’s Laboratories, Commercialising Dalbavancin RTD in the USA
Adalvo has recently signed a licensing and supply agreement with Dr. Reddy’s Laboratories to commercialise Dalbavancin Ready-to-Dilute (RTD) in the United States. Under this strategic agreement, Adalvo will license the exclusive...
- Business09 August 2024
Adalvo Secures DCP Approval for Ethinylestradiol/Drospirenone Tablets
Adalvo announces the successful DCP approval for Ethinylestradiol/Drospirenone 0.03mg /3mg tablets. Based on the reference brand Yasmin, Ethinylestradiol/Drospirenone has been developed in collaboration with one of our strategic partners. The INN is a...
- Business06 August 2024
Adalvo Successfully Launches DMF Across Global Markets
Adalvo has successfully launched Dimethyl Fumarate (DMF) across various markets, serving over 20 partners on three continents. Dimethyl Fumarate 120mg and 240mg hard capsules have been developed based on the reference brand Tecfidera,...
- Business29 July 2024
Adalvo Launches First and Only Pregabalin ER in Europe
Adalvo has successfully launched the first and only Pregabalin Extended-Release (ER) tablets in Europe. This differentiated product has been introduced in two major European markets, Germany and Spain, through partnerships...
- Business26 July 2024
Adalvo Announces Successful EU Approval for Mirabegron 50mg Prolonged-Release Tablets
Adalvo secures successful DCP approval for Mirabegron 50mg prolonged-release tablets. Developed based on the reference brand Betmiga prolonged-release tablets, Mirabegron is indicated for the treatment of urgency, increased micturition frequency, and/or...
- Business24 July 2024
Adalvo Launches Desmopressin ODT in Europe, First and Only Generic Alternative Since March 2024
Adalvo successfully launched the first and only Desmopressin Orally Disintegrating Tablets (ODT) in Europe in March 2024. Developed based on the reference brand Minirin Melt, Desmopressin ODT is indicated for the...
- Business18 July 2024
Adalvo Announces Early European Approval for Empagliflozin Film-Coated Tablets
Adalvo announces the successful earlier-than-expected DCP approval for Empagliflozin 10mg and 25mg film-coated tablets. Our product has been developed based on the reference brand Jardiance film-coated tablets, which are indicated for...
- Business15 July 2024
Adalvo Restarts DCP Procedure for Dapagliflozin Film-Coated Tablets
Adalvo announces the restart of the DCP procedure for Dapagliflozin Film-Coated Tablets, with an anticipated EU Marketing Authorisation approval date in October 2024. Developed based on the reference brand Forxiga film-coated...
- Business12 July 2024
Adalvo Announces Successful DCP Submission For Empagliflozin/Metformin Film-Coated Tablets
Adalvo announces the successful DCP submission for Empagliflozin/Metformin film-coated tablets, with an anticipated approval date in June 2025. Developed based on the reference brand Synjardy film-coated tablets, Empagliflozin/Metformin is indicated for...
- Business10 July 2024
Adalvo Secures DCP Approval for Apixaban Tablets
Adalvo announces the successful DCP approval for Apixaban Tablets. Based on the reference brand Eliquis, Apixaban is indicated for the treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)....
- Business03 July 2024
Adalvo Expands Portfolio with Voclosporin Soft Gel Capsules
Adalvo announces the addition of Voclosporin 7.9mg Soft Gel Capsules to its portfolio. Based on the reference brand Lupkynis, Voclosporin is indicated for treating adult patients with Lupus Nephritis (LN). Voclosporin represents the...
- Business02 July 2024
Adalvo Successfully Completes Pivotal BE Study for Azacitidine Film Coated Tablets
Adalvo announces the successful completion of the Pivotal BE study for Azacitidine 300mg film-coated tablets in adult patients with acute myeloid leukaemia (AML). Following the successful EU Pivotal BE study, Azacitidine...
- Sustainability01 July 2024
Embracing the Night: Deniz Kayadelen's Bold Journey to Conquer the Catalina Channel and Raise Awareness for Clean Water
As Deniz Kayadelen, Adalvo’s Brand Ambassador, prepares for her upcoming swim across the Catalina Channel on July 21st, we are reminded of the immense mental and physical challenges she faces....
- Business27 June 2024
Adalvo Prepares for Rapid Filing of Fidaxomicin
Adalvo advances in the development of Fidaxomicin Film Coated Tablets 200mg, expecting dossier completion within the next six months. Following this, Adalvo intends to immediately file Fidaxomicin, having DCP slots already secured for...
- Business24 June 2024
Adalvo Introduces Olaparib Film Coated Tablets to its Oncology Portfolio
Adalvo announces the addition of Olaparib Film Coated Tablets to its expanding oncology portfolio. As a leading PARP inhibitor, Olaparib has received the most FDA approvals across four tumor types, underscoring...
- Business20 June 2024
Adalvo Launches Rivaroxaban Film-Coated Tablets in the UK
Adalvo announces the successful launch of Rivaroxaban Film-Coated Tablets in the United Kingdom. Developed based on the reference brand Xarelto, Rivaroxaban is indicated for the prevention of atherothrombotic events in adult...